Compare KraneShares Hang Seng TECH Index ETF (KTEC) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Hang Seng TECH Index ETF vs Mesoblast Limited — how do they compare? KraneShares Hang Seng TECH Index ETF trades at $11.81 (market cap $45.04M), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Mesoblast Limited is far larger — about 38.9× KraneShares Hang Seng TECH Index ETF's market cap, and Mesoblast Limited is more actively traded (239,027 versus 29,043). Which is the better fit depends on your goals — on Pluang, investors hold KraneShares Hang Seng TECH Index ETF for 44 Days and Mesoblast Limited for 15 Days on average.
| KTEC | MESO | |
|---|---|---|
Market Cap | $45.04M | $1.75B |
Volume | 29,043 | 239,027 |
Sector | Sector/Thematic | Health |
52-Week High | $18.73 | $20.96 |
52-Week Low | $11.41 | $13.19 |
Typical Hold Time | 44 Days | 15 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KTEC trades at $11.81, up 1.99% with bearish technical signals from moving averages. The company reported $120.04M revenue in 2016 with improving net margin (-0.59% vs -4.88% in 2015) and positive operating cash flow of $5.81M. Recent news highlights China's AI competition potentially benefiting tech ETFs like KTEC.
KTEC shows operational improvement but faces profitability challenges with negative net income. The stock's technical weakness and volatile earnings history suggest cautious approach. Upside depends on sustained revenue growth and margin expansion in competitive tech ETF space.
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KraneShares Hang Seng TECH Index ETF
KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.
Read more on KTEC →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
